Login to Your Account

Gentium Shares Falling as Defibrotide Faces Delay Again

By Cormac Sheridan
Staff Writer

Friday, February 22, 2013
Shares in Gentium SpA fell 20 percent last week on news that the lengthy approval process for defibrotide, a drug for the treatment and prevention of hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem cell transplant, had just become longer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription